CardioDx Blood-Based Gene Expression Test Honored As One Of TIME Magazine’s Top Ten Medical Breakthroughs of 2010
PALO ALTO, Calif.--(BUSINESS WIRE)--CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced that Corus™ CAD, the company’s blood-based gene expression test, has been honored as one of TIME Magazine’s Top Ten Medical Breakthroughs of 2010.
Corus CAD is the first and only clinically validated blood-based test to help clinicians confidently identify which of their stable symptomatic patients are likely to need further assessment for obstructive coronary artery disease.
“We agree that we are in the midst of one of the most exciting areas of medicine today, and we’re pleased that the Corus CAD gene expression test has been recognized by both The Wall Street Journal, with a Technology Innovation Award earlier this year, and by TIME Magazine – two venerable American publications,” said David Levison, chief executive officer of CardioDx.
Corus CAD delivers valuable information to cardiologists making decisions about which patients require advanced imaging or potential catheterization, and to primary care clinicians deciding which patients need a specialist referral. These decisions are increasingly important as clinical and regulatory communities recognize the need to reduce radiation exposure from medical imaging.
A study published in the March 11, 2010 issue of the New England Journal of Medicine found that in nearly 400,000 patients who underwent elective invasive angiographic procedures, 62% were found to have no obstructive coronary artery blockage. The study authors concluded that current modalities for identifying which patients should undergo elective invasive coronary angiography to diagnose coronary artery disease have limitations, and that better methods are needed for patient risk stratification.
About Corus CAD
Corus CAD is the first and only clinically validated blood-based test for obstructive coronary artery disease. The test involves a routine blood draw conveniently administered in the clinician’s office and does not expose patients to risks of radiation or imaging agent intolerance. Corus CAD is a decision-making tool that can help primary care clinicians and cardiologists evaluate whether a non-diabetic patient's symptoms are due to obstructive coronary artery disease. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women.
The Corus CAD test procedure uses the RNA levels of 23 genes. Because the RNA levels are increased or decreased when obstructive coronary artery disease is present, Corus CAD is able to measure the likelihood that an individual patient has obstructive coronary artery disease from a simple blood sample.
Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the company’s CLIA-certified Palo Alto, Calif. laboratory. Test results are delivered promptly to the clinician’s office. Corus CAD is currently available in the United States.
For more information please visit http://www.cardiodx.com/media-kit/.
About Gene Expression Testing
Gene expression testing provides valuable tissue and cell-specific information about the molecular mechanisms involved in disease processes, enabling evaluation of an individual patient’s disease state, activity, and/or progression at a given point in time. Unlike genetic tests, which measure genetic variations, mutations, traits and predispositions – factors that are constant over a person’s lifetime – gene expression testing assesses a dynamic process, integrating both genetic predisposition and additional behavioral and environmental influences on current disease state.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. In 2010, the company was honored as a winner of the Wall Street Journal’s prestigious Technology Innovation Awards and one of TIME Magazine’s Top Ten Medical Breakthroughs. Privately held, CardioDx is funded by Kleiner, Perkins, Caufield & Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Company and GE Capital. For more information, please visit www.cardiodx.com.